Autoantibodies in Sjögren's Syndrome.

Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med (2003) 10.82

Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med (1994) 8.21

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79

Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A (1980) 7.33

Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum (2001) 4.06

Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol (1998) 3.68

Autoantibodies as predictors of disease. Lancet (2004) 2.15

Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) (2008) 1.92

Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med (2009) 1.85

Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest (1986) 1.83

Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest (2006) 1.76

Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum (2004) 1.76

Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74

Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J Immunol (2009) 1.73

Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun (2009) 1.66

Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol (1993) 1.64

Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med (1994) 1.58

Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc Natl Acad Sci U S A (1998) 1.55

Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum (2002) 1.53

Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun (2011) 1.46

TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol (2009) 1.45

Long-term Ro60 humoral autoimmunity in primary Sjögren's syndrome is maintained by rapid clonal turnover. Clin Immunol (2013) 1.44

Anti-Ro/SSA and La/SSB antibodies. Autoimmunity (2005) 1.43

Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. N Engl J Med (1985) 1.41

Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis (2004) 1.35

Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum (2009) 1.32

The Ro autoantigen binds misfolded U2 small nuclear RNAs and assists mammalian cell survival after UV irradiation. Curr Biol (2003) 1.32

Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med (2005) 1.31

The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol (2006) 1.30

The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. J Mol Med (Berl) (2004) 1.25

Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther (2010) 1.23

Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol (1998) 1.21

Sjögren's syndrome: studying the disease in mice. Arthritis Res Ther (2011) 1.21

Novel autoantibodies in Sjogren's syndrome. Clin Immunol (2012) 1.20

Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev (2010) 1.19

Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA (2013) 1.18

Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum (2000) 1.16

The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum (2001) 1.16

Serum and immunoglobulin G from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model. Pediatr Res (1998) 1.15

Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis (2012) 1.14

Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci (2001) 1.10

Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol (2002) 1.10

Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res (1997) 1.09

Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun (2012) 1.08

Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) (1999) 1.08

Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol (1998) 1.08

Current concepts: mouse models of Sjögren's syndrome. J Biomed Biotechnol (2010) 1.06

Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol (2007) 1.04

Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis. J Autoimmun (2011) 1.02

Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis (2008) 1.00

Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum (2010) 0.99

Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis. J Immunol (2011) 0.98

Anti-La (SS-B): a diagnostic criterion for Sjögren's syndrome? Clin Exp Rheumatol (1989) 0.97

Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun (2001) 0.96

Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol (2015) 0.95

Centromere protein C is a target of autoantibodies in Sjögren's syndrome and is uniformly associated with antibodies to Ro and La. J Rheumatol (2004) 0.94

Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis (2011) 0.93

Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome. Arthritis Rheum (2011) 0.92

β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol (2011) 0.92

Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol (1994) 0.92

Cardiac immunoglobulin deposition in congenital heart block associated with maternal anti-Ro autoantibodies. Am J Med (1987) 0.91

Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis (2002) 0.91

Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum (2006) 0.91

Clinical and laboratory features of anticentromere antibody positive primary Sjögren's syndrome. J Rheumatol (2001) 0.90

Clinical course of primary Sjögren's syndrome: salivary, oral, and serologic aspects. J Rheumatol (2000) 0.90

The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome. Ann Rheum Dis (2015) 0.90

Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus (2003) 0.90

Molecular mechanisms of congenital heart block. Exp Cell Res (2014) 0.89

Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol (2005) 0.88

Active immunological profile is associated with systemic Sjögren's syndrome. J Clin Immunol (2011) 0.88

Secreted human Ro52 autoantibody proteomes express a restricted set of public clonotypes. J Autoimmun (2012) 0.88

The role of intrinsic epithelial activation in the pathogenesis of Sjögren's syndrome. J Autoimmun (2010) 0.87

Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjögren's syndrome. J Rheumatol (2002) 0.87

Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis (2006) 0.87

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome. Acta Reumatol Port (2010) 0.86

Autoantibodies in the sicca syndrome (primary Sjögren's syndrome). Ann Rheum Dis (1984) 0.85

Relation of sensory peripheral neuropathy in Sjögren syndrome to anti-Ro/SSA. J Clin Rheumatol (2012) 0.85

Anti-alpha-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome. Arthritis Res Ther (2003) 0.84

Cholinergic autoantibodies from primary Sjögren's syndrome modulate submandibular gland Na+/K+-ATPase activity via prostaglandin E2 and cyclic AMP. Eur J Oral Sci (2010) 0.83

Anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis (2005) 0.82

Sjögren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol (2000) 0.82

Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. Arch Oral Biol (2011) 0.82

Autoantibody to NA14 is an independent marker primarily for Sjogren's syndrome. Front Biosci (Landmark Ed) (2009) 0.82

Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjögren's syndrome. Arthritis Rheumatol (2014) 0.81

An immunodominant La/SSB autoantibody proteome derives from public clonotypes. Clin Exp Immunol (2013) 0.81

Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome. Autoimmun Rev (2015) 0.81

Determination of the subset of Sjogren's syndrome with articular manifestations by anticyclic citrullinated peptide antibodies. J Rheumatol (2009) 0.80

Predictive and prognostic value of antinuclear antibodies and rheumatoid factor in primary Sjogren's syndrome. Int J Rheum Dis (2010) 0.80

IgA rheumatoid factor in primary Sjogren's syndrome. Scand J Rheumatol (2009) 0.80

Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol (2003) 0.80

Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren's syndrome. Clin Rheumatol (2011) 0.80

The value of animal models to study immunopathology of primary human Sjögren's syndrome symptoms. Expert Rev Clin Immunol (2014) 0.79

Discrimination between Sjögren's and non-Sjögren's sicca syndrome by sialoscintigraphy and antibodies against alpha-fodrin and Ro/La autoantigens. J Int Med Res (2009) 0.79

Passively acquired autoimmunity and the maternal fetal dyad in systemic lupus erythematosus. Springer Semin Immunopathol (1986) 0.79

Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med (2014) 0.79

Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance. Clin Exp Rheumatol (2010) 0.78

Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patients with Sjogren's syndrome. Br J Ophthalmol (2011) 0.78

Diagnostic accuracy of anti-alpha-fodrin antibodies for primary Sjögren's syndrome. Mod Rheumatol (2013) 0.78

Anti-proteasome activator 28alpha is a novel anti-cytoplasmic antibody in patients with systemic lupus erythematosus and Sjögren's syndrome. Mod Rheumatol (2009) 0.78

[Anti-centromere antibodies. Study of 67 positive sera]. Rev Med Interne (1992) 0.77